Gary Lyman
Medical Oncology · Seattle, WANPI 1770503054
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $98,510 of the $129,652 with a category attached, or 76.0%. 18 manufacturers reported payments, led by Sandoz at 36.2% of the total. Reporting peaked in 2019 at $34,141 and has fallen 63.6% since, to $12,434 in 2025. Among medical oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $1581.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sandoz$47K
- Samsung Bioepis Co., Ltd.$21K
- Astrazeneca UK Limited$14K
- E.r. Squibb & Sons, L.L.C.$13K
- AstraZeneca$8K
- Partner Therapeutics, Inc.$6K
- plus $22K from 12 others
Across 20 payments — averaging $9312.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$186K
What the payments were for
- Consulting fees$98,51076%
- Speaking & faculty fees$19,02215%
- Travel & lodging$9,8608%
- Food & beverage$2,2602%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sandoz | 26 | $46,987 |
| Samsung Bioepis Co., Ltd. | 7 | $20,677 |
| Astrazeneca UK Limited | 2 | $13,700 |
| E.r. Squibb & Sons, L.L.C. | 8 | $12,502 |
| AstraZeneca | 4 | $7,933 |
| Partner Therapeutics, Inc. | 3 | $6,125 |
| Fresenius Kabi USA, LLC | 5 | $5,010 |
| Jazz Pharmaceuticals Inc. | 1 | $4,432 |
| Spectrum Pharmaceuticals Inc. | 11 | $4,396 |
| Seagen Inc. | 1 | $3,439 |
| Merck | 2 | $2,500 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Dova Pharmaceuticals | 2 | $167 |
| Secura Bio, Inc. | 3 | $95 |
| Eli Lilly | 3 | $84 |
| Genentech USA, Inc. | 1 | $61 |
| Lilly USA, LLC | 1 | $32 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$129,652 in reported general payments places this provider in the 95th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
- Diane TsengSeattle$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.